LGM Pharma Expands U.S. Manufacturing, Bringing Total Investment to $15M Across Texas and Colorado Sites
LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, today announced the second phase of its CDMO growth strategy, committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado. The investment follows the company’s previously announced $6 million expansion in Rosenberg in 2025 and is designed to increase commercial capacity, expand R&D capabilities, and support continued demand for U.S.-based drug product manufacturing.
LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories
LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy. The expansion will increase capacity for liquid, suspension, semi-solid, and suppository drug products, addressing the rising demand for reliable U.S.-based production.
LGM Pharma Expands Analytical Testing Services with New Endotoxin and Rapid Sterility Testing Capabilities
LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, announced today the expansion of its Analytical Testing Services (ATS) with the addition of endotoxin and rapid sterility testing capabilities. These new services, now available at LGM Pharma’s Irvine, CA facility, offer significant benefits to drug developers, including accelerated turnaround times, enhanced quality control, and cost savings.
LGM Pharma Unveils Enhanced Analytical Testing Services and Expands CDMO Portfolio with Additional Suppository Manufacturing Capabilities
LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio. These strategic enhancements provide additional internal bandwidth for growth while also providing customers greater flexibility with a streamlined, efficient, and comprehensive solution for their manufacturing needs.
LGM Pharma Reports Strong Revenues in First Year of CDMO Operations Along With Continued Growth in Its API Sourcing Business
LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today reported strong growth in 2022 in both its long-established Active Pharmaceutical Ingredient (API) division and its new contract development and manufacturing (CDMO) division. LGM acquired its CDMO division in 2020, with full operational integration accomplished in late 2021 for commercial manufacturing and for the two newly-created CDMO service segments - Analytical Testing Services (ATS) and Drug Product Research & Development (R&D).
LGM Pharma’s Unique Mix of API Sourcing and CDMO Services Is Fueling Robust Growth
LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, today reported that its unique mix of active pharmaceutical ingredient (API) sourcing and contract development and manufacturing (CDMO) services is helping to drive robust growth. Leveraging synergies and accelerating growth were key drivers of LGM Pharma’s 2020 acquisition of a formulation development and finished dose CDMO to complement the company’s global API sourcing business.
LGM Pharma Launches Standalone Analytical Services for Drug Developers and Manufacturers
LGM Pharma today announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies. The company, which already conducts analytical services as part of its integrated contract development and manufacturing (CDMO) activities, now is offering its analytical services expertise and facilities as a standalone contract service for pharmaceutical industry clients.
